BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (NOVEMBER DECEMBER 2012)

Compensation for Injuries To Human Subjects-Impact on Clinical Trials

M. D. Nair

Introduction:
 
A topic of considerable concern in recent times has been the issue of carrying out Clinical trials on voluntary subjects (both healthy as well as sick) with experimental drugs under development. It is now an accepted fact that such trials are unavoidable if new drugs are to be discovered and developed. It is also understood that human trials with unproved products entail considerable risks to the human subjects including possible not probable fatality in spite of all safeguards based on experimental data on animals. Even if it is assured that all needed precautions at ensuring safety, there have been several instances of major tragedies. How does the system compensate for such injuries to the affected individuals, groups and even communities? The issue is broader since injuries to humans occur under a variety of conditions, not all of them within human control. What are the issues involved and what would be the fairest method of deciding on the nature and quantum of compensations. As a relatively new entrant to clinical trials on Indian subjects how are our policies , strategies and legislations going to handle this issue?. How does it affect drug discovery and development, an extremely vital area of interest to the Indian Pharmaceutical industry?

 

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.